Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: December 2014

Chapter 14 - Thrombolysis

from Section 2 - Special considerations in pediatric patients

Summary

Introduction

Therapeutic application of the physiologic process of fibrinolysis (thrombolysis) was first attempted in the late 1950s in individuals with various thrombotic lesions, comprising peripheral venous, arterial, central nervous system (CNS) and coronary involvement [1]. Over time and after rigorous clinical study, intravascular thrombolysis has come to occupy a critical role in the management of thrombotic disease in adults, with clear, approved indications for acute myocardial infarction, stroke and massive pulmonary embolism (PE). Its utility has also been investigated recently via controlled clinical trials in adults with occlusive lower extremity deep vein thrombosis (DVT), with promising results [2]; current guidelines also suggest its use in selected patients with this common condition [3].

For many reasons, however, including the lower incidence of thrombotic disease, consequent difficulty in completing high-quality clinical trials and heightened concerns for bleeding risks in young infants and children, the indications, dosing regimens and safety profiles for thrombolysis in pediatric patients are not as well established. Overall, the quality of evidence supporting the clinical management of pediatric patients via thrombolysis remains low given that a large proportion of the existing literature consists of individual case reports and small case series. Most series have reported on clinically heterogeneous groups of patients, with varied sites of vascular involvement using a variety of thrombolytic dosing regimens and modalities. Several comprehensive literature reviews have been published compiling available safety, efficacy and dosing data from several hundred infants and children [4–6]. Other recent review articles [7–9] summarize experience, expert opinion and important clinical management principles, while practice guidelines [10,11] are available to provide formal recommendations based on existing evidence.

References
Ouriel, K. A history of thrombolytic therapy. J Endovasc Ther 2004 Dec;11(Suppl 2):II128–II133.
Enden, T, Haig, Y, Klow, NE, Slagsvold, CE, Sandvik, L, Ghanima, W, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012 Jan 7;379(9810):31–8.
Jaff, MR, McMurtry, MS, Archer, SL, Cushman, M, Goldenberg, N, Goldhaber, SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011 Apr 26;123(16):1788–830.
Leaker, M, Massicotte, MP, Brooker, LA, Andrew, M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost 1996 Aug;76(2):132–4.
Nowak-Gottl, U, Auberger, K, Halimeh, S, Junker, R, Klinge, J, Kreuz, WD, et al. Thrombolysis in newborns and infants. Thromb Haemost 1999 Sep;82(Suppl 1):112–16.
Albisetti, M. Thrombolytic therapy in children. Thromb Res 2006;118(1):95–105.
Manco-Johnson, MJ. How I treat venous thrombosis in children. Blood 2006 Jan 1;107(1):21–9.
Raffini, L. Thrombolysis for intravascular thrombosis in neonates and children. Curr Opin Pediatr 2009 Feb;21(1):9–14.
Williams, MD. Thrombolysis in children. Br J Haematol 2010 Jan;148(1):26–36.
Manco-Johnson, MJ, Grabowski, EF, Hellgreen, M, Kemahli, AS, Massicotte, MP, Muntean, W, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002 Jul;88(1):157–8.
Monagle, P, Chan, AK, Goldenberg, NA, Ichord, RN, Journeycake, JM, Nowak-Gottl, U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 Feb;141(2 Suppl):e737S–801S.
Hoylaerts, M, Rijken, DC, Lijnen, HR, Collen, D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982 Mar 25;257(6):2912–19.
Bouma, BN, Marx, PF, Mosnier, LO, Meijers, JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001 Mar 1;101(5):329–54.
Albisetti, M. The fibrinolytic system in children. Semin Thromb Hemost 2003 Aug;29(4):339–48.
Andrew, M, Paes, B, Milner, R, Johnston, M, Mitchell, L, Tollefsen, DM, et al. Development of the human coagulation system in the full-term infant. Blood 1987 Jul;70(1):165–72.
Edelberg, JM, Enghild, JJ, Pizzo, SV, Gonzalez-Gronow, M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990 Jul;86(1):107–12.
Ries, M, Easton, RL, Longstaff, C, Zenker, M, Morris, HR, Dell, A, et al. Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin. Thromb Res 2002 Feb 1;105(3):247–56.
Manco-Johnson, MJ, Nuss, R, Hays, T, Krupski, W, Drose, J, Manco-Johnson, ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000 Apr;136(4):446–53.
Kennedy, LA, Drummond, WH, Knight, ME, Millsaps, MM, Williams, JL. Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator. J Pediatr 1990 May;116(5):798–801.
Andrew, M, Brooker, L, Leaker, M, Paes, B, Weitz, J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992 Sep 7;68(3):325–30.
Goldenberg, NA, Knapp-Clevenger, R, Manco-Johnson, MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004 Sep 9;351(11):1081–8.
Choi, M, Massicotte, MP, Marzinotto, V, Chan, AK, Holmes, JL, Andrew, M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 2001 Jul;139(1):152–6.
Ragni, MV, Journeycake, JM, Brambilla, DJ. Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis. Haemophilia 2008 Jan;14(1):30–8.
Dillon, PW, Jones, GR, Bagnall-Reeb, HA, Buckley, JD, Wiener, ES, Haase, GM. Prophylactic urokinase in the management of long-term venous access devices in children: a Children’s Oncology Group study. J Clin Oncol 2004 Jul 1;22(13):2718–23.
Gupta, AA, Leaker, M, Andrew, M, Massicotte, P, Liu, L, Benson, LN, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001 Nov;139(5):682–8.
Leary, SE, Harrod, VL, de Alarcon, PA, Reiss, UM. Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients. J Pediatr Hematol/Oncol 2010 Mar;32(2):97–102.
Newall, F, Browne, M, Savoia, H, Campbell, J, Barnes, C, Monagle, P. Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics. J Pediatr Hematol/Oncol 2007 Apr;29(4):269–73.
Manco-Johnson, MJ, Grabowski, EF, Hellgreen, M, Kemahli, AS, Massicotte, MP, Muntean, W, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002 Jul;88(1):157–8.
Zenz, W, Arlt, F, Sodia, S, Berghold, A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost 1997;23(3):321–32.
Theiss, W, Wirtzfeld, A, Fink, U, Maubach, P. The success rate of fibrinolytic therapy in fresh and old thrombosis of the iliac and femoral veins. Angiology 1983 Jan;34(1):61–9.
Goldenberg, NA, Branchford, B, Wang, M, Ray, C, Durham, JD, Manco-Johnson, MJ. Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism. J Vasc Interv Radiol 2011 Feb;22(2):121–32.
Hoffmeister, HM, Szabo, S, Helber, U, Seipel, L. The thrombolytic paradox. Thromb Res 2001 Sep 30;103(Suppl 1):S51–55.
Gast, A, Tschopp, TB, Schid, G, Hilpert, K, Ackermann, J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46–6240), recombinant hirudin and heparin in human plasma. Blood Coag Fibrinolysis 1994;5:879–87.
Torr, SR, Nachowiak, DA, Fujii, S, Sobel, BE. “Plasminogen steal” and clot lysis. J Am Coll Cardiol 1992 Apr;19(5):1085–90.
Bovill, EG, Becker, R, Tracy, RP. Monitoring thrombolytic therapy. Prog Cardiovasc Dis 1992 Jan;34(4):279–94.
Monagle, P, Chalmers, E, Chan, A, deVeber, G, Kirkham, F, Massicotte, P, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edn). Chest 2008 Jun;133(6 Suppl):887S–968S.
Wang, M, Hays, T, Balasa, V, Bagatell, R, Gruppo, R, Grabowski, EF, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol/Oncol 2003 May;25(5):379–86.
Goldenberg, NA, Durham, JD, Knapp-Clevenger, R, Manco-Johnson, MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of post-thrombotic syndrome in children. Blood 2007 Jul 1;110(1):45–53.
Rosenschein, U, Rozenszajn, LA, Kraus, L, Marboe, CC, Watkins, JF, Rose, EA, et al. Ultrasonic angioplasty in totally occluded peripheral arteries. Initial clinical, histological, and angiographic results. Circulation 1991 Jun;83(6):1976–86.
Atar, S, Rosenschein, U. Perspectives on the role of ultrasonic devices in thrombolysis. J Thromb Thrombolysis 2004 Apr;17(2):107–14.
Lin, PH, Annambhotla, S, Bechara, CF, Athamneh, H, Weakley, SM, Kobayashi, K, et al. Comparison of percutaneous ultrasound-accelerated thrombolysis versus catheter-directed thrombolysis in patients with acute massive pulmonary embolism. Vascular 2009 Nov;17(Suppl 3):S137–147.
Vedantham, S, Vesely, TM, Parti, N, Darcy, M, Hovsepian, DM, Picus, D. Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy. J Vasc Interv Radiol 2002 Oct;13(10):1001–8.
Lin, PH, Zhou, W, Dardik, A, Mussa, F, Kougias, P, Hedayati, N, et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. Am J Surg 2006 Dec;192(6):782–8.
O’Sullivan, GJ, Lohan, DG, Gough, N, Cronin, CG, Kee, ST. Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter. J Vasc Interv Radiol 2007 Jun;18(6):715–24.
Goldenberg, NA, Donadini, MP, Kahn, SR, Crowther, M, Kenet, G, Nowak-Gottl, U, et al. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 2010 Nov;95(11):1952–9.
Watson, LI, Armon, MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2004;(4):CD002783.
Kearon, C, Akl, EA, Comerota, AJ, Prandoni, P, Bounameaux, H, Goldhaber, SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 Feb;141(2 Suppl): e419S–e494S.
Manco-Johnson, MJ, Goldenberg, NA. 2–10–2013. (Personal Communication.)
Farnoux, C, Camard, O, Pinquier, D, Hurtaud-Roux, MF, Sebag, G, Schlegel, N, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1998 Jul;133(1):137–40.
Levy, M, Benson, LN, Burrows, PE, Bentur, Y, Strong, DK, Smith, J, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991 Mar;118(3):467–72.
Smets, K, Vanhaesebrouck, P, Voet, D, Schelstraete, P, Govaert, P. Use of tissue type plasminogen activator in neonates: case reports and review of the literature. Am J Perinatol 1996 May;13(4):217–22.
Biss, TT, Brandao, LR, Kahr, WH, Chan, AK, Williams, S. Clinical features and outcome of pulmonary embolism in children. Br J Haematol 2008 Sep;142(5):808–18.
Kuo, WT, Gould, MK, Louie, JD, Rosenberg, JK, Sze, DY, Hofmann, LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009 Nov;20(11):1431–40.
Coombs, CJ, Richardson, PW, Dowling, GJ, Johnstone, BR, Monagle, P. Brachial artery thrombosis in infants: an algorithm for limb salvage. Plast Reconstr Surg 2006 Apr 15;117(5):1481–8.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 Dec 14;333(24):1581–7.
Marler, JR, Tilley, BC, Lu, M, Brott, TG, Lyden, PC, Grotta, JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000 Dec 12;55(11):1649–55.
Uyttenboogaart, M, Vroomen, PC, Stewart, RE, De, KJ, Luijckx, GJ. Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci 2007 Mar 15;254 (1–2):28–32.
Hacke, W, Kaste, M, Bluhmki, E, Brozman, M, Davalos, A, Guidetti, D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 Sep 25;359(13):1317–29.
Del Zoppo, GJ, Saver, JL, Jauch, EC, Adams, HPExpansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009 Aug;40(8):2945–8.
Shellhaas, RA, Smith, SE, O’Tool, E, Licht, DJ, Ichord, RN. Mimics of childhood stroke: characteristics of a prospective cohort. Pediatrics 2006 Aug;118(2):704–9.
Roach, ES, Golomb, MR, Adams, R, Biller, J, Daniels, S, deVeber, G, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008 Sep;39(9):2644–91.
Amlie-Lefond, C, deVeber, G, Chan, AK, Benedict, S, Bernard, T, Carpenter, J, et al. Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study. Lancet Neurol 2009 Jun;8(6):530–6.
Byrnes, JW, Williams, B, Prodhan, P, Erdem, E, James, C, Williamson, R, et al. Successful intra-arterial thrombolytic therapy for a right middle cerebral artery stroke in a 2-year-old supported by a ventricular assist device. Transpl Int 2012 Mar;25(3):e31–e33.
Tan, M, Armstrong, D, Birken, C, Bitnun, A, Caldarone, CA, Cox, P, et al. Bacterial endocarditis in a child presenting with acute arterial ischemic stroke: should thrombolytic therapy be absolutely contraindicated?Dev Med Child Neurol 2009 Feb;51(2):151–4.
Kirton, A, Wong, JH, Mah, J, Ross, BC, Kennedy, J, Bell, K, et al. Successful endovascular therapy for acute basilar thrombosis in an adolescent. Pediatrics 2003 Sep;112(3 Pt 1): e248–e251.
Janjua, N, Nasar, A, Lynch, JK, Qureshi, AI. Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample. Stroke 2007 Jun;38(6):1850–4.
Wasay, M, Dai, AI, Ansari, M, Shaikh, Z, Roach, ES. Cerebral venous sinus thrombosis in children: a multicenter cohort from the United States. J Child Neurol 2008 Jan;23(1):26–31.
Dentali, F, Squizzato, A, Gianni, M, De Lodovici, ML, Venco, A, Paciaroni, M, et al. Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost 2010 Nov;104(5):1055–62.
Mallick, AA, Sharples, PM, Calvert, SE, Jones, RW, Leary, M, Lux, AL, et al. Cerebral venous sinus thrombosis: a case series including thrombolysis. Arch Dis Child 2009 Oct;94(10):790–4.
Waugh, J, Plumb, P, Rollins, N, Dowling, MM. Prolonged direct catheter thrombolysis of cerebral venous sinus thrombosis in children: a case series. J Child Neurol 2012 Mar;27(3):337–45.
Andrew, M, Paes, B, Johnston, M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol/Oncol 1990;12(1):95–104.
Zenz, W, Muntean, W, Beitzke, A, Zobel, G, Riccabona, M, Gamillscheg, A. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children. Br Heart J 1993 Oct;70(4):382–5.
Hartmann, J, Hussein, A, Trowitzsch, E, Becker, J, Hennecke, KH. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001 Jul;85(1):F18–F22.
Balaguru, D, Dilawar, M, Ruff, P, Radtke, WA. Early and late results of thrombolytic therapy using tissue-type plasminogen activator to restore arterial pulse after cardiac catheterization in infants and small children. Am J Cardiol 2003 Apr 1;91(7):908–10.
Cannon, BC, Kertesz, NJ, Friedman, RA, Fenrich, AL. Use of tissue plasminogen activator in a stroke after radiofrequency ablation of a left-sided accessory pathway. J Cardiovasc Electrophysiol 2001 Jun;12(6):723–5.
Carlson, MD, Leber, S, Deveikis, J, Silverstein, FS. Successful use of rt-PA in pediatric stroke. Neurology 2001 Jul 10;57(1):157–8.
Cremer, S, Berliner, Y, Warren, D, Jones, AE. Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature. CJEM 2008 Nov;10(6):575–88.
Heil, JW, Malinowski, L, Rinderknecht, A, Broderick, JP, Franz, D. Use of intravenous tissue plasminogen activator in a 16-year-old patient with basilar occlusion. J Child Neurol 2008 Sep;23(9):1049–53.
Jain, SV, Morton, LD. Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator. Pediatr Neurol 2008 Feb;38(2):126–9.
Losurdo, G, Giacchino, R, Castagnola, E, Gattorno, M, Costabel, S, Rossi, A, et al. Cerebrovascular disease and varicella in children. Brain Dev 2006 Jul;28(6):366–70.
Muniz, AE. Thrombolytic therapy for acute stroke in a teenager. Pediatr Emerg Care 2012 Feb;28(2):170–3.
Noser, EA, Felberg, RA, Alexandrov, AV. Thrombolytic therapy in an adolescent ischemic stroke. J Child Neurol 2001 Apr;16(4):286–8.
Sampaio, I, Abecasis, F, Quintas, S, Moreno, T, Camilo, C, Vieira, M, et al. Successful intravenous thrombolysis in a 14-year-old boy with ischemic stroke. Pediatr Emerg Care 2011 Jun;27(6):541–3.
Shuayto, MI, Lopez, JI, Greiner, F. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke. J Child Neurol 2006 Jul;21(7):604–6.
Thirumalai, SS, Shubin, RA. Successful treatment for stroke in a child using recombinant tissue plasminogen activator. J Child Neurol 2000 Aug;15(8):558.